Oncology

ESCAT v2 Makes Resistance Clinically Actionable
ESMO has updated its international framework for molecular actionability and introduced a parallel evidence scale for resistance biomarkers. The change reflects a simple reality: sequencing reports need to communicate not only what may work, but what the evidence says probably will not.

Enhertu Stumbles in Early Breast Cancer

Endometrial Cancer Gets a Strong ADC Win

Divarasib Raises the KRAS G12C Bar

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

Skin Cancer AI Has Crossed a Line: It Is Discharging Patients on Its Own

Precision Oncology Has a Scale Problem

One in Eight Cancers Starts With an Infection

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases